Systematic Review Of Intravenous Imunoglobulin In Rh Hemolytic Disease Of The Newborn

Objectives: To assess the effectiveness of high dose intravenousimmunoglobulin (HDIVIG) in reducing the need for exchange transfusion(ET) in neonates with proven hemolytic disease due to Rh incompatibility.To assess the effectiveness of HDIVIG in reducing the duration ofphototherapy and hospital stay.Design: Systematic review of randomized controlled trials whichcompared HDIVIG and phototherapy with phototherapy alone that appliedto neonates with Rh incompatibility.Results: Six randomized controlled trials were found including348neonates。There was no significant decrease in the rate of infants thatrequired exchange transfusion in the HDIVIG group [RR=0.62,(95%CI:0.31～1.24)],but significant decrease in hospital stay and duration ofphototherapy [WMD=-1.40，(95%CI:-1.70～-1.11)]，[WMD=-1.24，(95%CI:-1.45～-1.04)].Conclusion：The efficacy of intravenous immune globulin used totreat neonatal Rh hemolytic disease in reducing the need of ET was notsignificant. But hospital stay and duration of phototherapy were reducedsignificantly.